chief-commercial-officer
(5)
Philip Auerbach
Philip Auerbach is the Chief Marketing Officer of Custom Ink, the Fairfax, Virginia custom apparel and promotional products company, a role he took up in May 2025. A Cornell-trained marketer with roughly 25 years of executive experience, he spent nearly 15 years at McKinsey & Company, where he became a partner in the Sales & Marketing practice and co-founded the firm's Loyalty service, before running commercial and digital operations at Caesars Entertainment, Lindblad Expeditions, Dunkin' Brands, ClearChoice, and Bumble. At Bumble he led global marketing and partnerships and helped scale the business profitably by more than 50%, contributing to over $900 million in annual revenue. At Custom Ink he owns brand strategy, performance marketing, and customer acquisition.
Daniel Wagner
Daniel (Dan) Wagner is a medical device and biotechnology executive who leads Otolith Labs, the Washington, DC company building the OtoBand, a non-invasive wearable that uses patented non-invasive Vestibular Resonance Therapy (nVRT) to address chronic vertigo. With more than two decades of commercial experience spanning 60-plus countries and roles at Spark Biomedical, Olympus Corporation, HeartSciences and Signature Biologics, Wagner advised Otolith for over five years before joining full-time as Chief Commercial Officer in 2024 and now serves as Chief Executive Officer, steering the company's go-to-market strategy toward a planned market launch.
Kelly Thompson
Kelly Thompson is a food industry executive with more than 30 years of experience who led Incredo (formerly DouxMatok), the sugar-reduction technology company behind Incredo Sugar. Trained as a food engineer at the University of Wisconsin-Madison, she built her career in research, development and quality at Kraft Foods, WhiteWave Foods and Continental Mills before joining Incredo in 2022 to head North America. She rose to Chief Commercial Officer and Chief Executive Officer, steering the commercialization of a real-cane-sugar ingredient that lets manufacturers cut sugar by up to half while keeping the taste.
Akira Robinson
Akira Robinson is a biotech and pharmaceutical commercialization leader with roughly two decades of experience turning early-stage science into market-ready medicine. He is a Partner and Chief Experience Officer at the life-sciences consultancy Scimitar Inc. and serves as interim Chief Commercial Officer at Nucleus RadioPharma. He built and scaled the launch practice at EVERSANA to more than 20 consultants, and has stepped into interim CCO and COO seats across the industry. With a Harvard biochemistry degree, a Johns Hopkins biotech master's, and a stint as a Wall Street biotech equity analyst, he blends scientific fluency with commercial operating chops, lately focused on radiopharmaceutical therapies and AI-driven commercialization.
Sebby Borriello
Sebby Borriello is a pharmaceutical and medical-device commercialization veteran with 30-plus years of go-to-market leadership. After 25 years at Johnson & Johnson across wound management, biosurgery and aesthetics, he helped turn South Korea's SK Life Science from an R&D-only shop into a fully integrated US pharma company, leading the 2020 launch of its first FDA-approved drug, the epilepsy treatment XCOPRI. He later advised and joined Carmell Therapeutics as Chief Business Officer, and today serves as Executive Vice President and Chief Commercial Officer at MIDAS Healthcare Solutions, a New York startup tackling medication diversion and drug-waste accountability through its MidasVIEW platform and Anytime Witness video-verification technology.